Redmile Group’s Pfizer PFE Stock Holding History

Redmile Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,328,462	Closed	-$40.7M	–	54
2015 Q4	$40.7M	Buy	+1,328,462	New	+$41.8M	3.04%	14

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group's PFE Position: Q2 2016 in Review

Redmile Group sold out of Pfizer (PFE) in Q2 2016, closing a stake of 130,485 shares — an estimated $3.67M sold.

Redmile Group first reported a position in PFE in Q4 2013 and held it in 3 quarters. The position peaked at $16.4M in Q4 2013. 1,991 funds tracked by Wall St. Rank hold PFE as of Q2 2016.

Redmile Group reported no remaining Pfizer position as of Q2 2016 after selling out during the quarter.
Redmile Group sold 130,485 Pfizer shares in Q2 2016, an estimated $3.67M.
Redmile Group first reported a position in Pfizer in Q4 2013 and held it in 3 quarters.
Redmile Group's Pfizer position peaked at $16.4M in Q4 2013.
1,991 funds tracked by Wall St. Rank held Pfizer as of Q2 2016.

Based on Redmile Group's 13F filing for Q2 2016, filed 16 Aug 2016.